TrialThe Lancet. Neurology2013

An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study.

Timothy M Miller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.